These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 30587450)
1. Lead generation and optimization of novel GPR119 agonists with a spirocyclic cyclohexane structure. Harada K; Mizukami J; Watanabe T; Mori G; Ubukata M; Suwa K; Fukuda S; Negoro T; Sato M; Inaba T Bioorg Med Chem Lett; 2019 Feb; 29(3):373-379. PubMed ID: 30587450 [TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of novel and potent GPR119 agonists with a spirocyclic structure. Harada K; Mizukami J; Kadowaki S; Matsuda I; Watanabe T; Oe Y; Kodama Y; Aoki K; Suwa K; Fukuda S; Yata S; Inaba T Bioorg Med Chem Lett; 2018 Apr; 28(7):1228-1233. PubMed ID: 29519733 [TBL] [Abstract][Full Text] [Related]
3. Optimization of oxadiazole derivatives with a spirocyclic cyclohexane structure as novel GPR119 agonists. Harada K; Mizukami J; Watanabe T; Mori G; Ubukata M; Suwa K; Fukuda S; Negoro T; Sato M; Inaba T Bioorg Med Chem Lett; 2019 Aug; 29(16):2100-2106. PubMed ID: 31288965 [TBL] [Abstract][Full Text] [Related]
4. Discovery of a novel trans-1,4-dioxycyclohexane GPR119 agonist series. Han S; Narayanan S; Kim SH; Calderon I; Zhu X; Kawasaki A; Yue D; Lehmann J; Wong A; Buzard DJ; Semple G; Carroll C; Chu ZL; Al-Sharmma H; Shu HH; Tung SF; Unett DJ; Behan DP; Yoon WH; Morgan M; Usmani KA; Chen C; Sadeque A; Leonard JN; Jones RM Bioorg Med Chem Lett; 2015 Aug; 25(15):3034-8. PubMed ID: 26048791 [TBL] [Abstract][Full Text] [Related]
5. Polar aromatic periphery increases agonist potency of spirocyclic free fatty acid receptor (GPR40) agonists inspired by LY2881835. Krasavin M; Lukin A; Bagnyukova D; Zhurilo N; Golovanov A; Zozulya S; Zahanich I; Moore D; Tikhonova IG Eur J Med Chem; 2017 Feb; 127():357-368. PubMed ID: 28076825 [TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological evaluation of novel 7-azaspiro[3.5]nonane derivatives as GPR119 agonists. Matsuda D; Kawamura M; Kobashi Y; Shiozawa F; Suga Y; Fusegi K; Nishimoto S; Kimura K; Miyoshi M; Takayama N; Kakinuma H; Ohtake N Bioorg Med Chem; 2018 May; 26(8):1832-1847. PubMed ID: 29486951 [TBL] [Abstract][Full Text] [Related]
7. The optimization of xanthine derivatives leading to HBK001 hydrochloride as a potent dual ligand targeting DPP-IV and GPR119. Li G; Meng B; Yuan B; Huan Y; Zhou T; Jiang Q; Lei L; Sheng L; Wang W; Gong N; Lu Y; Ma C; Li Y; Shen Z; Huang H Eur J Med Chem; 2020 Feb; 188():112017. PubMed ID: 31926470 [TBL] [Abstract][Full Text] [Related]
8. Discovery of novel pyrimidine and malonamide derivatives as TGR5 agonists. Park EJ; Ahn YG; Jung SH; Bang HJ; Kim M; Hong DJ; Kim J; Suh KH; Kim YJ; Kim D; Kim EY; Lee K; Min KH Bioorg Med Chem Lett; 2014 Sep; 24(17):4271-5. PubMed ID: 25082126 [TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and structure-activity relationship studies of GPR40 agonists containing amide linker. Chen T; Ning M; Ye Y; Wang K; Leng Y; Shen J Eur J Med Chem; 2018 May; 152():175-194. PubMed ID: 29705709 [TBL] [Abstract][Full Text] [Related]
10. Discovery and optimization of a novel series of GPR142 agonists for the treatment of type 2 diabetes mellitus. Lizarzaburu M; Turcotte S; Du X; Duquette J; Fu A; Houze J; Li L; Liu J; Murakoshi M; Oda K; Okuyama R; Nara F; Reagan J; Yu M; Medina JC Bioorg Med Chem Lett; 2012 Sep; 22(18):5942-7. PubMed ID: 22884988 [TBL] [Abstract][Full Text] [Related]
11. Spirooxindoles as novel 3D-fragment scaffolds: Synthesis and screening against CYP121 from M. tuberculosis. Davis HJ; Kavanagh ME; Balan T; Abell C; Coyne AG Bioorg Med Chem Lett; 2016 Aug; 26(15):3735-40. PubMed ID: 27287372 [TBL] [Abstract][Full Text] [Related]
13. The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470). Hamdouchi C; Kahl SD; Patel Lewis A; Cardona GR; Zink RW; Chen K; Eessalu TE; Ficorilli JV; Marcelo MC; Otto KA; Wilbur KL; Lineswala JP; Piper JL; Coffey DS; Sweetana SA; Haas JV; Brooks DA; Pratt EJ; Belin RM; Deeg MA; Ma X; Cannady EA; Johnson JT; Yumibe NP; Chen Q; Maiti P; Montrose-Rafizadeh C; Chen Y; Reifel Miller A J Med Chem; 2016 Dec; 59(24):10891-10916. PubMed ID: 27749056 [TBL] [Abstract][Full Text] [Related]
14. Discovery of novel xanthine compounds targeting DPP-IV and GPR119 as anti-diabetic agents. Li G; Huan Y; Yuan B; Wang J; Jiang Q; Lin Z; Shen Z; Huang H Eur J Med Chem; 2016 Nov; 124():103-116. PubMed ID: 27560285 [TBL] [Abstract][Full Text] [Related]
15. Discovery and optimization of N-(3-(1,3-dioxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-4-yloxy)phenyl)benzenesulfonamides as novel GPR119 agonists. Yu M; Ken Zhang J; Wang Y; Zhu J; Kayser F; Medina JC; Siegler K; Conn M; Shan B; Grillo MP; Coward P; Jim Liu J Bioorg Med Chem Lett; 2014 Jan; 24(1):156-60. PubMed ID: 24332491 [TBL] [Abstract][Full Text] [Related]
16. Synthesis and SAR studies of bicyclic amine series GPR119 agonists. Sakairi M; Kogami M; Torii M; Kataoka H; Fujieda H; Makino M; Kataoka D; Okamoto R; Miyazawa T; Okabe M; Inoue M; Takahashi N; Harada S; Watanabe N Bioorg Med Chem Lett; 2012 Aug; 22(15):5123-8. PubMed ID: 22765901 [TBL] [Abstract][Full Text] [Related]
17. Design and biological evaluation of tetrahydropyridine derivatives as novel human GPR119 agonists. Zuo Z; Chen M; Shao X; Qian X; Liu X; Zhou X; Xiang J; Deng P; Li Y; Jie H; Liu C; Cen X; Xie Y; Zhao Y Bioorg Med Chem Lett; 2020 Feb; 30(4):126855. PubMed ID: 31898998 [TBL] [Abstract][Full Text] [Related]
18. Discovery of structurally novel, potent and orally efficacious GPR119 agonists. Alper P; Azimioara M; Cow C; Mutnick D; Nikulin V; Michellys PY; Wang Z; Reding E; Paliotti M; Li J; Bao D; Zoll J; Kim Y; Zimmerman M; Groessel T; Tuntland T; Joseph SB; McNamara P; Seidel HM; Epple R Bioorg Med Chem Lett; 2014 May; 24(10):2383-7. PubMed ID: 24751443 [TBL] [Abstract][Full Text] [Related]
19. Discovery of 6,7-dihydro-5H-pyrrolo[2,3-a]pyrimidines as orally available G protein-coupled receptor 119 agonists. Katamreddy SR; Carpenter AJ; Ammala CE; Boros EE; Brashear RL; Briscoe CP; Bullard SR; Caldwell RD; Conlee CR; Croom DK; Hart SM; Heyer DO; Johnson PR; Kashatus JA; Minick DJ; Peckham GE; Ross SA; Roller SG; Samano VA; Sauls HR; Tadepalli SM; Thompson JB; Xu Y; Way JM J Med Chem; 2012 Dec; 55(24):10972-94. PubMed ID: 23214471 [TBL] [Abstract][Full Text] [Related]
20. Optimization of a novel series of potent and orally bioavailable GPR119 agonists. Koshizawa T; Morimoto T; Watanabe G; Watanabe T; Yamasaki N; Sawada Y; Fukuda T; Okuda A; Shibuya K; Ohgiya T Bioorg Med Chem Lett; 2017 Aug; 27(15):3249-3253. PubMed ID: 28648463 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]